@article {7526,
	title = {American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Tra},
	journal = {Biology of Blood and Marrow Transplantation},
	volume = {21},
	year = {2015},
	note = {Cited By :19Export Date: 21 February 2017},
	month = {2015},
	pages = {2039 - 2051},
	abstract = {In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, (3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move the research agenda forward. After reviewing the available data, the expert committee came to the following consensus statement for salvage autologous HCT: (1) In transplantation-eligible patients relapsing after primary therapy that did NOT include an autologous HCT, high-dose therapy with HCT as part of salvage therapy should be considered standard; (2) High-dose therapy and autologous HCT should be considered appropriate therapy for any patients relapsing after primary therapy that includes an autologous HCT with initial remission duration of more than 18 months; (3) High-dose therapy and autologous HCT can be used as a bridging strategy to allogeneic HCT; (4) The role of postsalvage HCT maintenance needs to be explored in the context of well-designed prospective trials that should include new agents, such as monoclonal antibodies, immune-modulating agents, and oral proteasome inhibitors; (5) Autologous HCT consolidation should be explored as a strategy to develop novel conditioning regimens or post-HCT strategies in patients with short (less than 18 months remissions) after primary therapy; and (6) Prospective randomized trials need to be performed to define the role of salvage autologous HCT in patients with MM relapsing after primary therapy comparing it to "best non-HCT" therapy. The expert committee also underscored the importance of collecting enough hematopoietic stem cells to perform 2 transplantations early in the course of the disease. Regarding allogeneic HCT, the expert committee agreed on the following consensus statements: (1) Allogeneic HCT should be considered appropriate therapy for any eligible patient with early relapse (less than 24 months) after primary therapy that included an autologous HCT and/or high-risk features (ie, cytogenetics, extramedullary disease, plasma cell leukemia, or high lactate dehydrogenase); (2) Allogeneic HCT should be performed in the context of a clinical trial if possible; (3) The role of postallogeneic HCT maintenance therapy needs to be explored in the context of well-designed prospective trials; and (4) Prospective randomized trials need to be performed to define the role salvage allogeneic HCT in patients with MM relapsing after primary therapy. {\textcopyright} 2015 American Society for Blood and Marrow Transplantation.},
	keywords = {myeloma, Salvage therapy, Stem cell transplantation},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84947430469\&doi=10.1016\%2fj.bbmt.2015.09.016\&partnerID=40\&md5=b212f2eccbaf40d5ad235146e059a5ee},
	author = {Giralt, S. and Garderet, L. and Durie, B. and Cook, G. and Gahrton, G. and Bruno, B. and Hari, P. and Lokhorst, H. and McCarthy, P. and Krishnan, A. and Sonneveld, P. and Goldschmidt, H. and Jagannath, S. and Barlogie, B. and Mateos, M. and Gimsing, P. and Sezer, O. and Mikhael, J. and Lu, J. and Dimopoulos, M. and Mazumder, A. and Palumbo, A. and Abonour, R. and Anderson, K. and Attal, M. and Blade, J. and Bird, J. and Cavo, M. and Comenzo, R. and De La Rubia, J. and Einsele, H. and Garcia-Sanz, R. and Hillengass, J. and Holstein, S. and Johnsen, H.E. and Joshua, D. and Koehne, G. and Kumar, S. and Kyle, R. and Leleu, X. and Lonial, S. and Ludwig, H. and Nahi, H. and Nooka, A. and Orlowski, R. and Rajkumar, V. and Reiman, A. and Richardson, P. and Riva, E. and San Miguel, J. and Turreson, I. and Usmani, S. and Vesole, D. and Bensinger, W. and Qazilbash, M. and Efebera, Y. and Mohty, M. and Gasparreto, C. and Gajewski, J. and LeMaistre, C.F. and Bredeson, C. and Moreau, P. and Pasquini, M. and Kroeger, N. and Stadtmauer, E.}
}
